COMPANY Data
Movers and SHAKERS

Ticker | ONTX (Nasdaq) |
Current Price | $1.25 ↓ -0.11 |
Market Cap | 295.77M |
Price Target | $2.10 |
Volume | 37.03M |
52wk Range | $0.20 - $1.93 |
ADVANCED MARKET DATA |

Advanced Market Data
Onconova Therapeutics Inc. (ONTX)




Overview
Onconova Therapeutics is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova’s novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and a dose-escalation and expansion Phase 1 trial is planned in the U.S. to commence in the first half of 2021. Onconova’s product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab. Preclinical work with rigosertib in COVID-19 is ongoing as well. Although some preclinical experiments with rigosertib in cellular models demonstrated marked inhibition of SARS-CoV-2 replication, we do not anticipate conducting clinical trials with rigosertib in COVID-19 without securing additional funding. For more information, please visit www.onconova.com.
- Industry/Sector Report
- Corporate Presentation
- Corporate Events
- Press Releases/News Feed
- ChannelCAST Videos [2]
- Senior Equity Research Analyst
- Corporate Filings
Onconova Therapeutics Inc. Corporate Filings
Onconova Therapeutics Inc. Corporate Events
Onconova Therapeutics Inc. Press Releases / News Feed
Channelchek
Not available
Channelchek
No reports available
Noble Capital Markets Analyst
FINRA licenses 7, 63, 86, 87.
Full Bio & Coverage List